Dorsey & Whitney Trust CO LLC acquired a new position in Laboratory Corporation of America Holdings (NYSE:LH) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,462 shares of the medical research company’s stock, valued at approximately $226,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Regentatlantic Capital LLC increased its stake in shares of Laboratory Corporation of America Holdings by 0.5% in the second quarter. Regentatlantic Capital LLC now owns 1,696 shares of the medical research company’s stock worth $261,000 after purchasing an additional 8 shares in the last quarter. Endurance Wealth Management Inc. increased its stake in shares of Laboratory Corporation of America Holdings by 0.7% in the first quarter. Endurance Wealth Management Inc. now owns 1,510 shares of the medical research company’s stock worth $217,000 after purchasing an additional 10 shares in the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of Laboratory Corporation of America Holdings by 0.6% in the first quarter. Oppenheimer & Co. Inc. now owns 2,411 shares of the medical research company’s stock worth $346,000 after purchasing an additional 15 shares in the last quarter. New Amsterdam Partners LLC NY increased its stake in shares of Laboratory Corporation of America Holdings by 0.7% in the second quarter. New Amsterdam Partners LLC NY now owns 3,847 shares of the medical research company’s stock worth $593,000 after purchasing an additional 27 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its stake in shares of Laboratory Corporation of America Holdings by 0.8% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 4,143 shares of the medical research company’s stock worth $594,000 after purchasing an additional 31 shares in the last quarter. 93.21% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently issued reports on LH shares. ValuEngine cut shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Saturday, June 3rd. Barclays PLC increased their price objective on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. BidaskClub upgraded shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. Credit Suisse Group restated a “buy” rating and set a $146.00 target price on shares of Laboratory Corporation of America Holdings in a research report on Sunday, May 28th. Finally, Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $164.00.

COPYRIGHT VIOLATION NOTICE: “Dorsey & Whitney Trust CO LLC Acquires New Position in Laboratory Corporation of America Holdings (LH)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/17/dorsey-whitney-trust-co-llc-acquires-new-position-in-laboratory-corporation-of-america-holdings-lh.html.

Laboratory Corporation of America Holdings (NYSE:LH) opened at 153.60 on Friday. The company’s 50 day moving average is $156.60 and its 200-day moving average is $147.65. Laboratory Corporation of America Holdings has a 12 month low of $119.51 and a 12 month high of $164.22. The company has a market cap of $15.64 billion, a price-to-earnings ratio of 21.51 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.40 by $0.07. The company had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.36 EPS. On average, analysts expect that Laboratory Corporation of America Holdings will post $9.54 earnings per share for the current fiscal year.

In other news, CEO David P. King sold 44,687 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $156.86, for a total transaction of $7,009,602.82. Following the completion of the sale, the chief executive officer now owns 258,753 shares of the company’s stock, valued at $40,587,995.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider F Samuel Eberts III sold 31,500 shares of the company’s stock in a transaction on Friday, August 25th. The stock was sold at an average price of $155.22, for a total transaction of $4,889,430.00. Following the sale, the insider now directly owns 31,894 shares of the company’s stock, valued at approximately $4,950,586.68. The disclosure for this sale can be found here. In the last three months, insiders sold 222,968 shares of company stock valued at $34,980,922. 0.90% of the stock is owned by insiders.

Laboratory Corporation of America Holdings Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.